A Randomized, Double Masked, Uncontrolled , Multicenter Phase I/II Study to Evaluate Safety and Tolerability of PAN-90806 Eye Drops, Suspension in Treatment-Naive Participants With Neovascular Age-Related Macular Degeneration (AMD)
Latest Information Update: 24 Jul 2020
At a glance
- Drugs PAN 90806 (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors PanOptica
- 10 Oct 2019 According to a PanOptica media release, topline results from this study were presented at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology annual meeting (OIS@AAO, in San Francisco).
- 10 Oct 2019 Topline results presented in a PanOptica media release.
- 07 Oct 2019 According to a PanOptica media release, the company will present topline data from this study at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology (OIS@AAO, 10th Oct 2019, in San Francisco).